EligibleTrials

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Recruiting · NCT07438496 · Interventional (participants receive a specific treatment) · Lead sponsor: Janssen Research & Development, LLC

View the official record on ClinicalTrials.gov →
Lupus

Interventions studied

NipocalimabPlaceboStandard of care treatment

What this trial is about

The purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs).

Who can take part

Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

60 locations listed across 13 US states.

Showing 60 of 249 listed sites. See the official record for the complete list.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.